# Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

> **NCT04443010** · PHASE1,PHASE2 · RECRUITING · sponsor: **Philogen S.p.A.** · enrollment: 226 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Onfekafusp alfa
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04443010
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-20
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 226 (ESTIMATED)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04443010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04443010, "Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04443010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*